piracetam has been researched along with Disorders of Excessive Somnolence in 12 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Disorders of Excessive Somnolence: Disorders characterized by hypersomnolence during normal waking hours that may impair cognitive functioning. Subtypes include primary hypersomnia disorders (e.g., IDIOPATHIC HYPERSOMNOLENCE; NARCOLEPSY; and KLEINE-LEVIN SYNDROME) and secondary hypersomnia disorders where excessive somnolence can be attributed to a known cause (e.g., drug affect, MENTAL DISORDERS, and SLEEP APNEA SYNDROME). (From J Neurol Sci 1998 Jan 8;153(2):192-202; Thorpy, Principles and Practice of Sleep Medicine, 2nd ed, p320)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To prospectively assess the safety and efficacy of levetiracetam in patients with uncontrolled focal epilepsy, in a common practice-based setting." | 9.12 | Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial. ( Despland, PA; Fejerman, N; Genton, P; Maubrey, MC; Peltola, J; Rektor, I; Sadzot, B; Schlit, AF; Steinhoff, B; van Hammée, G; van Paesschen, W; Vandervelden, C; Wroe, S, 2006) |
| " In Phase II/III trials, the adverse effects occurring more commonly in the treatment groups versus the placebo group were; somnolence (14." | 6.42 | Levetiracetam safety profiles and tolerability in epilepsy patients. ( Briggs, DE; French, JA, 2004) |
| "To prospectively assess the safety and efficacy of levetiracetam in patients with uncontrolled focal epilepsy, in a common practice-based setting." | 5.12 | Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial. ( Despland, PA; Fejerman, N; Genton, P; Maubrey, MC; Peltola, J; Rektor, I; Sadzot, B; Schlit, AF; Steinhoff, B; van Hammée, G; van Paesschen, W; Vandervelden, C; Wroe, S, 2006) |
| " We could not demonstrate any association between the paradoxical effect of levetiracetam and type of epilepsy or the antiepileptic comedication used." | 3.74 | The risk of paradoxical levetiracetam effect is increased in mentally retarded patients. ( Barcs, G; Clemens, Z; Fabó, D; Holló, A; Jakus, R; Janszky, J; Kelemen, A; Rásonyi, G; Szucs, A, 2008) |
| "We report a patient with focal epilepsy in whom increased sleep needs (hypersomnia) developed in the absence of subjective excessive daytime sleepiness (EDS) during an add-on treatment with levetiracetam (LEV)." | 3.73 | Hypersomnia in an epilepsy patient treated with levetiracetam. ( Bassetti, CL; Khatami, R; Siegel, AM, 2005) |
| "Levetiracetam proved to be an effective and well-tolerated add-on treatment in this group of children with refractory epilepsy." | 2.73 | Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study. ( Arts, WF; Augustijn, P; Brouwer, OF; Callenbach, PM; Geerts, AT; Geerts, Y; Gunning, WB; Peeters, EA; Stroink, H; ten Houten, R; Weber, AM, 2008) |
" Adverse events reported after IV administration of LEV (| 2.72 | Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. ( Daoust, A; Lu, ZS; Otoul, C; Ramael, S; Stockis, A; Toublanc, N; Troenaru, M, 2006) | |
| "Levetiracetam was discontinued in 4." | 2.53 | Safety of Levetiracetam in Paediatrics: A Systematic Review. ( Choonara, I; Egunsola, O; Sammons, HM, 2016) |
| " In Phase II/III trials, the adverse effects occurring more commonly in the treatment groups versus the placebo group were; somnolence (14." | 2.42 | Levetiracetam safety profiles and tolerability in epilepsy patients. ( Briggs, DE; French, JA, 2004) |
| "Daytime somnolence was reported by 28 patients, 15 on OXC (10%); 8 received oral modafinil for the same, while none discontinued this AED." | 1.43 | Behavioral effects and somnolence due to levetiracetam versus oxcarbazepine - a retrospective comparison study of North Indian patients with refractory epilepsy. ( Agarwal, P; Gupta, A; Poornima, S; Shukla, G, 2016) |
| "Levetiracetam-treated patients commonly report daytime drowsiness, fatique, asthenia and decreasing of motor activity." | 1.34 | Comparison of motor activity and sleep in patients with complex partial seizures on levetiracetam treatment and a group of healthy subjects. ( Yilmaz, H, 2007) |
| "Levetiracetam is a potent and generally well tolerable new antiepileptic drug which is also efficacious in patients with difficult-to-treat focal epilepsies." | 1.32 | [Levetiracetam in combined therapy for focal epilepsy: experience with 80 patients]. ( Fauser, S; Feil, B; Homberg, V; Schulze-Bonhage, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (75.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Egunsola, O | 1 |
| Choonara, I | 1 |
| Sammons, HM | 1 |
| Shukla, G | 1 |
| Gupta, A | 1 |
| Agarwal, P | 1 |
| Poornima, S | 1 |
| Zhou, JY | 1 |
| Tang, XD | 1 |
| Huang, LL | 1 |
| Zhong, ZQ | 1 |
| Lei, F | 1 |
| Zhou, D | 1 |
| Schulze-Bonhage, A | 1 |
| Feil, B | 1 |
| Fauser, S | 1 |
| Homberg, V | 1 |
| Briggs, DE | 1 |
| French, JA | 1 |
| Khatami, R | 1 |
| Siegel, AM | 1 |
| Bassetti, CL | 1 |
| Genton, P | 1 |
| Sadzot, B | 1 |
| Fejerman, N | 1 |
| Peltola, J | 1 |
| Despland, PA | 1 |
| Steinhoff, B | 1 |
| Rektor, I | 1 |
| Wroe, S | 1 |
| Maubrey, MC | 1 |
| Vandervelden, C | 1 |
| van Hammée, G | 1 |
| Schlit, AF | 1 |
| van Paesschen, W | 1 |
| Yardimci, N | 1 |
| Karatas, M | 1 |
| Kilinc, M | 1 |
| Benli, S | 1 |
| Ramael, S | 1 |
| Daoust, A | 1 |
| Otoul, C | 1 |
| Toublanc, N | 1 |
| Troenaru, M | 1 |
| Lu, ZS | 1 |
| Stockis, A | 1 |
| Yilmaz, H | 1 |
| Callenbach, PM | 1 |
| Arts, WF | 1 |
| ten Houten, R | 1 |
| Augustijn, P | 1 |
| Gunning, WB | 1 |
| Peeters, EA | 1 |
| Weber, AM | 1 |
| Stroink, H | 1 |
| Geerts, Y | 1 |
| Geerts, AT | 1 |
| Brouwer, OF | 1 |
| Szucs, A | 1 |
| Clemens, Z | 1 |
| Jakus, R | 1 |
| Rásonyi, G | 1 |
| Fabó, D | 1 |
| Holló, A | 1 |
| Barcs, G | 1 |
| Kelemen, A | 1 |
| Janszky, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Trial Studying the Safety and Efficacy of Keppra® as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy[NCT00630968] | Phase 4 | 1,541 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Intravenous Levetiracetam as First-line Anticonvulsive Treatment in Patients With Non-convulsive Status Epilepticus[NCT00603135] | Phase 2 | 0 participants (Actual) | Interventional | 2008-01-31 | Withdrawn | ||
| A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury[NCT04836481] | 20 participants (Anticipated) | Observational | 2021-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for piracetam and Disorders of Excessive Somnolence
| Article | Year |
|---|---|
Safety of Levetiracetam in Paediatrics: A Systematic Review.
Topics: Adolescent; Anticonvulsants; Child; Disorders of Excessive Somnolence; Epilepsy; Humans; Levetiracet | 2016 |
Levetiracetam safety profiles and tolerability in epilepsy patients.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Aged; Animals; Anticonvulsants; Astheni | 2004 |
3 trials available for piracetam and Disorders of Excessive Somnolence
| Article | Year |
|---|---|
Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial.
Topics: Adult; Anticonvulsants; Disorders of Excessive Somnolence; Dizziness; Dose-Response Relationship, Dr | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
Topics: Adolescent; Anticonvulsants; Child; Disorders of Excessive Somnolence; Dose-Response Relationship, D | 2008 |
7 other studies available for piracetam and Disorders of Excessive Somnolence
| Article | Year |
|---|---|
Behavioral effects and somnolence due to levetiracetam versus oxcarbazepine - a retrospective comparison study of North Indian patients with refractory epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Disorders of Excessive Somnolence; Drug Re | 2016 |
The acute effects of levetiracetam on nocturnal sleep and daytime sleepiness in patients with partial epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Disorders of Excessive Somnolence; Electroencephalography; | 2012 |
[Levetiracetam in combined therapy for focal epilepsy: experience with 80 patients].
Topics: Adult; Anticonvulsants; Combined Modality Therapy; Disease-Free Survival; Disorders of Excessive Som | 2004 |
Hypersomnia in an epilepsy patient treated with levetiracetam.
Topics: Adult; Anticonvulsants; Disorders of Excessive Somnolence; Drug Therapy, Combination; Epilepsies, Pa | 2005 |
Levetiracetam in Meige's syndrome.
Topics: Anticonvulsants; Botulinum Toxins, Type A; Brain; Disorders of Excessive Somnolence; Dose-Response R | 2006 |
Comparison of motor activity and sleep in patients with complex partial seizures on levetiracetam treatment and a group of healthy subjects.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Disorders of Excessive Somnolence; Electroencephalography; | 2007 |
The risk of paradoxical levetiracetam effect is increased in mentally retarded patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Disorders of Excessive Somnolence; Dizziness; Drug | 2008 |